Author/Authors :
Nasiripour, Somayyeh Clinical Pharmacy Department - Faculty of Pharmacy - Tehran University of Medical Sciences and Health Services, Tehran , Gholami, kheirollah Clinical Pharmacy Department - Faculty of Pharmacy -Tehran University of Medical Sciences and Health Services and Research Center for Rational Use of Drugs, Tehran , Mousavi, Sarah Department of Clinical Pharmacy and Pharmacy Practice - Faculty of Pharmacy and Pharmaceutical Sciences - Isfahan University of Medical Sciences, Isfahan , Mohagheghi, Abbas Department of Cardiology - Shariati Hospital - Tehran University of Medical Sciences, Tehran , Radfar, Mania Clinical Pharmacy Department - Faculty of Pharmacy - Tehran University of Medical Sciences and Health Services, Tehran , Abdollahi, Mohammad Faculty of Pharmacy and Pharmaceutical Sciences Research Centre - Tehran University of Medical Sciences, Tehran , Khazaeipour, Zahra Brain and Spinal Cord Injury Research Center - Imam Khomeini Hospital Complex - Tehran University of Medical Sciences, Tehran , Vahabzadeh, Gelareh Department of Pharmacology - Iran University of Medical Sciences, Tehran , Mojtahedzadeh, Mojtaba Clinical Pharmacy Department - Faculty of Pharmacy - Tehran University of Medical Sciences and Health Services, Tehran - Faculty of Pharmacy and Pharmaceutical Sciences Research Centre - Tehran University of Medical Sciences, Tehran
Abstract :
Heparin and enoxaparin possess anti-inflammatory properties. We compared the effects of these drugs on inflammatory biomarkers in patients with ST-segment Elevated Myocardial Infarction (STEMI). Thirty four patients with STEMI randomly separated in two groups and received standard doses of heparin and enoxaparin. The serum concentration of Serum Amyloid A (SAA), C-Reactive Protein (CRP), Interleukin (IL)-6, ferritin and Myeloperoxidase (MPO) were measured at baseline ,12 ,24 and 48 hours after drug administration. Serum concentrations of SAA (P: 0.02), CRP (P: 0.02) and ferritin (P: 0.01) significantly reduced in heparin group during measurements compared to baseline, circulating levels of IL-6 (P: 0.002), SAA (P: 0.009), CRP (P: 0.01) were significantly decreased in enoxaparin group. The overall difference in inflammatory biomarkers between heparin and enoxaparin group was not significant.
Both heparin and enoxaparine reduced serum levels of inflammatory biomarkers in patients with STEMI. This effect may provide additional clinical benefit of these drugs in the treatment of STEMI patients.
Keywords :
Heparin , Enoxaparin , Acute coronary syndrome , STEMI , Inflammatory biomarkers
